GO
Loading...

AstraZeneca PLC

More

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • AstraZeneca says DOJ closes probe into drug trial Tuesday, 19 Aug 2014 | 12:39 PM ET

    WASHINGTON— British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The London- based drugmaker said in a statement Tuesday: " AstraZeneca has always had absolute confidence in the integrity of the PLATO trial."

  • LONDON/ MELBOURNE- The world's biggest mining company, BHP Billiton, announces plans to spin off businesses worth an estimated $16 billion, most of them acquired in a 2001 merger, to focus on its most profitable activities.

  • UPDATE 1-U.S. clears AstraZeneca over heart drug trial Tuesday, 19 Aug 2014 | 3:24 AM ET

    LONDON, Aug 19- The U.S. government has cleared AstraZeneca Plc over a major clinical trial used to win marketing approval for its important new heart drug Brilinta, following an investigation which had cast a shadow over its prospects.

  • U.S. clears AstraZeneca over heart drug trial Tuesday, 19 Aug 2014 | 2:31 AM ET

    LONDON, Aug 19- AstraZeneca said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned.

  • LONDON, Aug 15- U.S. investors are withdrawing billions of dollars from European stocks as signs of a stalled economic recovery, compounded by the Ukraine crisis, halt the past year's scramble to buy back into the region.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • UPDATE 2-Rigel eye drug fails mid-stage study, shares fall Wednesday, 13 Aug 2014 | 10:48 AM ET

    Aug 13- Rigel Pharmaceuticals Inc said it would stop testing its drug for some patients with dry eye disease after the treatment failed a mid-stage study. British drugmaker AstraZeneca Plc scrapped its licensing deal for Rigel's rheumatoid arthritis treatment in June 2013.

  • Aug 13- Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease, sending its shares down 10.7 percent in premarket trading. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment in June 2013.

  • Aug 8- Pharmaceutical giant Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public.

  • *Advair restored to Express Scripts 2015 formulary list. LONDON, Aug 4- GlaxoSmithKline received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015..

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • *Investors focused on possible Pfizer return. LONDON, July 31- AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • DUBLIN, July 30- Ireland is in the firing line from Washington again for luring U.S. companies to its shores for tax benefits, but despite contrite noises coming from Dublin, it has too much to lose to discourage U.S. firms bent on shifting their tax domiciles.

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • Early movers: S, TWTR, AXP, GM, MAR, NFLX & more Wednesday, 30 Jul 2014 | 7:45 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, July 30- AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

  • AstraZeneca announces Almirall deal worth up to $2.1B Wednesday, 30 Jul 2014 | 2:24 AM ET

    AstraZeneca took steps to build up its respiratory medicine business by striking a deal to acquire the rights to lung drugs developed by Almirall.